Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2)

Zhonghua Pei,[†] Rohan Mendonca,[†] Lewis Gazzard,[†] Richard Pastor,[†] Leanne Goon,[§] Amy Gustafson,[§] Erica VanderPorten,[§] Georgia Hatzivassiliou,[‡] Kevin Dement,^{||} Robert Cass,^{||} Po-wai Yuen,[#] Yamin Zhang,[#] Guosheng Wu,[#] Xingyu Lin,[#] Yichin Liu,[§] and Benjamin D. Sellers^{*,†,||}

[†]Department of Discovery Chemistry, [§]Department of Biochemical and Cellular Pharmacology, ^{||}Department of Drug Metabolism and Pharmacokinetics, and [‡]Department of Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

[#]Pharmaron-Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China

Supporting Information

ABSTRACT: Tryptophan 2,3-dioxygenase 2 (TDO2) catalyzes the conversion of tryptophan to the immunosuppressive metabolite kynurenine. TDO2 overexpression has been observed in a number of cancers; therefore, TDO inhibition may be a useful therapeutic intervention for cancers. We identified an aminoisoxazole series as potent TDO2 inhibitors from a high-throughput screen (HTS). An extensive medicinal chemistry effort revealed that both the amino group and the isoxazole moiety are important for TDO2 inhibitory activity. Computational modeling yielded a binding hypothesis and provided insight into the observed structure–activity relationships. The optimized compound **21** is a potent TDO2 inhibitor with modest selectivity over indoleamine 2,3-dioxygenase 1 (IDO1) and with improved human whole blood stability.

KEYWORDS: Cancer immunotherapy, IDO, TDO, heme, enzyme

One of the critical functions of the immune system is to detect and eliminate malignant cells as they arise and develop antigenic mutations. For tumor cells to survive, the host immune system must be rendered functionally tolerant to otherwise immunogenic tumor-associated antigens. To accomplish this, tumors have been shown to enlist an array of endogenous host regulatory pathways.¹ One of these pathways is mediated by catabolism of the essential amino acid tryptophan (Trp) into kynurenine (Kyn), a process driven by the rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1) and Trp-2,3-dioxygenase 2 (TDO2).² These enzymes catalyze the oxidation of L-tryptophan to N-formyl kynurenine (NFK), which rapidly converts to kynurenine. Overexpression of these enzymes has been observed in several cancers and is thought to mitigate the immune response toward these tumors.^{3,4}

The enzymatic functions of IDO1 and TDO2 lead to multiple immune-related responses. IDO1-mediated Trp depletion activates GCN2 kinase,⁵ which in turn phosphorylates and inactivates the transcription factor eIF2 α leading to the blockade of protein translation and inhibition of cell proliferation. Kyn accumulation, however, activates the aryl hydrocarbon receptor (AhR),⁶ a transcription factor implicated in cancer progression, invasion, and immune suppression.² The overall result of IDO1 activity is induction of the regulatory T cell (Treg) compartment of the immune system, with concomitant inhibition of the effector T cell (Teff) compart-

ment. IDO1-deficiency (gene ablation or small molecule inhibition) has been shown to boost Teff and decrease Treg function in several autoimmunity and *in vivo* tumor models.^{7–9}

The physiological function of TDO2 includes the regulation of systemic Trp levels as well as liver Kyn levels. *In vitro* and *in vivo* studies suggest that TDO2 plays a role in promoting tumor cell survival and motility, and that TDO2-expressing tumors have a lower degree of T cell infiltrate that allows them to escape immune rejection.^{4,10} Genetic knockout or treatment of mice with a tool enzymatic inhibitor of TDO2 activity resulted in increased sensitivity of mice to endotoxin-induced shock, consistent with a role for TDO2 in suppressing inflammation and maintaining immune homeostasis.¹¹ In tumors, TDO2 activity is highly expressed in liver cancer and glioblastoma and upregulated in several other cancers.^{4,12} Thus, IDO1 and TDO2 inhibitors may represent a useful therapeutic intervention that restores the immune response against tumors, especially when combined with immune checkpoint inhibitors. Indeed, nonclinical data demonstrates that IDO1 and anti-PD-L1 dual inhibition shows markedly greater efficacy in activating the immune system and inhibiting tumor growth than either treatment alone, with a response associated with more pronounced activation of intratumoral CD8⁺ T cells, including

Received: October 22, 2017

Accepted: April 2, 2018

Published: April 2, 2018

proliferation and cytokine production.^{13,14} Preliminary data of a phase I/II clinical trial in melanoma where the IDO1 inhibitor epacadostat is being tested in combination with anti-PD1 has shown promising results in terms of response rates and depth of responses, compared to anti-PD-1 data.¹⁵

While several classes of IDO1 inhibitors have been disclosed in the literature,^{16–20} at the onset of our program, TDO2 inhibitors had been explored to a far lesser extent.²¹ Several patent applications describing either TDO-selective or IDO/TDO dual inhibitors have appeared since.^{22–26} TDO2 inhibition alone or in combination with IDO1 inhibition may allow fuller suppression of the kynurenine pathway across a range of tumor types. Here, we report our efforts in identifying and optimizing aminoisoxazole-based TDO2 inhibitors.

A high-throughput screen of the Genentech compound library identified a number of related aminoisoxazoles as inhibitors of TDO2. Inhibitory potency was measured in both biochemical and cellular assays of IDO1 and TDO2. In the biochemical assays, inhibitors were incubated with recombinant enzymes in the presence of the substrate tryptophan. The production of the *N*-formylkynurenine (NFK) was detected either in a fluorescence- or mass spec-based assay, and inhibitory potency was expressed as IC₅₀ values. In the cellular assays, inhibitors were incubated with either SW48 cells (in which endogenous TDO2 is highly expressed) or A172 cells (in which IDO1 is highly expressed upon induction by IFN γ). The production of NFK released from cells into the media was detected by a fluorescence-based assay, and the inhibitory potency was expressed as EC₅₀ values. The cytotoxicity of compounds was also measured for the same treated cells with a luminescence-based assay detecting cellular ATP levels. Since TDO2 biochemical potency was poorly predictive of cellular potency for the aminoisoxazole compounds (see Figure S1 in Supporting Information), our medicinal chemistry designs were consequently guided by cellular potency. As a counter screen to identify inhibition as a result of cytotoxicity, we assessed cell viability of SW48 and A172 cells by measuring intracellular ATP concentration. We found that the aminoisoxazoles generally do not affect intracellular ATP concentrations up to 25 μ M inhibitor concentration in a cell viability assay, indicating that the cellular potency was not caused by cytotoxicity of the inhibitors.

Aminoisoxazole **1** was the most potent hit found (cellular EC₅₀ of 85 nM, Table 1). We first investigated the importance of the amino group on the isoxazole moiety. Removal of the amino group (**2**) resulted in complete loss of potency. Addition of a methyl group on the nitrogen atom (**3**) resulted in a modest $\sim$ 8-fold reduction of potency. Replacement with a primary amide (**4**), secondary amide (**5**), hydroxymethyl group (**6**), or addition of a methyl group to the isoxazole 3-position (**7**) all resulted in significant reduction of TDO2 inhibitory potency.

We next investigated substitution and replacement of the phenyl moiety of compound **1**. Introduction of *p*-Cl (**8**), *p*-F (**9**), *m*-Cl (**10**), or *m*-methoxy (**11**) on the phenyl ring reduced TDO2 cell potency (Table 2). Replacing the phenyl group with a cyclopentyl (**12**) resulted in $\sim$ 4-fold reduction of potency, while a cyclohexyl (**13**) reduced the potency by 18-fold. Since more hydrophilic compounds tend to have better metabolic stability, we were interested in introducing groups that are more polar than the phenyl group. Pyridyl analogs (**14** and **15**) resulted in more than 10-fold reduction of potency. Between the two thiophenyl regioisomers, cellular potency of 3-

Table 1. TDO2 Cellular and Biochemical Potencies of the Aminoisoxazole Modifications

Compound	R ¹	TDO2 EC ₅₀ (μ M) ^a	TDO2 IC ₅₀ (μ M) ^b
1		0.085	0.14
2		>25	>25
3		0.67	0.19
4		>25	>25
5		>25	>25
6		18	4.4
7		9.7	25

^aCellular potency. ^bBiochemical potency. IC₅₀ and EC₅₀ values are the averages of at least two independent experiments.

thiophenyl **17** was much better than 2-thiophenyl **16**. The unsubstituted pyrazole (**18**) was $\sim$ 2.6-fold less potent than the corresponding phenyl analog **1**, while addition of a methyl group at either the C3 or C4 of the pyrazole (**19** and **20**) resulted in further erosion of TDO2 potency. However, introduction of a fluorine substituent at C4 of the pyrazole led to the most potent TDO2 inhibitor **21** within the aminoisoxazole series, with a cellular EC₅₀ of 77 nM.

Because the isoxazole core was found to exhibit poor stability in whole blood (*vide infra*), we investigated replacement of the 5-aminoisoxazole moiety with alternate heterocycles. Given that the amino group is required in the 5-aminoisoxazole for TDO2 potency (Table 1), the amino group was retained in all the designed heterocyclic targets. However, all azoles tested, including 4-aminoisoxazole (**22**), 3-aminopyrazoles (**23** and **24**), 3-amino-1,2,4-triazole (**25**), 4-amino-1,2,3-triazole (**26**), 4-aminoisothiazole (**27**), 5-aminoisothiazole (**28**), 5-amino-1,2,3-thiadiazole (**29**), and 4-amino-1,2,3-thiadiazole (**30**), were inactive against TDO2 (Table 3). We concluded that the 5-aminoisoxazole is a structurally unique core that is required for TDO2 inhibition.

To better understand the structure–activity relationships and develop a binding mode hypothesis, we constructed a model of **21** bound to human TDO2 (Figure 1) using the X-ray crystal structure, PDB 5TI9.²⁷ Our model predicts a binding mode with interactions similar to those of tryptophan. The primary amine, isoxazole ring nitrogen, and fluoropyrazole moiety in **21** correspond with the ammonium, carboxylate, and indole ring of tryptophan, respectively. In addition, the internal strain energy in this pose was found to be at the global energy minimum

Table 2. TDO2 Cellular and Biochemical Potencies of Phenyl Ring Substitution or Replacements

Compound	R ²	TDO2 EC ₅₀ (μM) ^a	TDO2 IC ₅₀ (μM) ^b
8		0.95	0.83
9		0.21	0.58
10		0.25	0.50
11		1.5	3.1
12		0.36	0.64
13		1.5	7.8
14		1.4	2.3
15		0.82	1.7
16		0.81	0.029
17		0.099	0.028
18		0.23	0.29
19		0.81	1.6
20		0.34	1.6
21		0.077	0.34

^aCellular potency. ^bBiochemical potency. IC₅₀ and EC₅₀ values are the averages of at least two independent experiments.

using quantum mechanical calculations (Figure S2). The strong interaction between the primary amine and the heme propionic acid in the model of **21** could explain the requirement for a primary or secondary amine as observed in Table 1. Small, hydrophobic replacements of the 4-fluoropyrazole in **21** would fit in the pocket (Table 2), while larger substituents such as the methoxy group in **11** would extend further than the tryptophan indole to experience a steric clash, thus explaining the increase

Table 3. TDO2 Cellular and Biochemical Potencies of Isoxazole Replacement

Compound	R ³	TDO2 EC ₅₀ (μM) ^a	TDO2 IC ₅₀ (μM) ^b
1		0.085	0.14
22		>25	>25
23		>25	>25
24		>25	>25
25		>25	>25
26		>25	>25
27		>25	>25
28		>25	18
29		>25	>25
30		>25	0.27

^aCellular potency. ^bBiochemical potency. IC₅₀ and EC₅₀ values are the averages of at least two independent experiments.

Figure 1. Binding mode hypothesis for compound **21**. X-ray structure (PDB: 5TI9) of human TDO2 (purple) is shown with heme (gray), tryptophan substrate (gray), and O₂ (red). A putative bound conformation for compound **21** (orange) was then modeled (see methods in the Supporting Information for details). Distances are in Angstroms.

in both IC₅₀ and EC₅₀ of **11**. Finally, the model predicts important interactions between the isoxazole heteroatoms and Arg144, which could explain the general loss of potency when

either of these atoms were replaced with hydrogen-bond donors or were methylated as in **22–24** and **26–27**. The predicted interactions with Arg144 may also explain the measurable biochemical activities in thiazole **28** or thiadiazole **30**. Triazole **25** maintained the two hydrogen bond acceptors of the isoxazole, but the nitrogen-linked ring was predicted to adopt an alternate low-energy conformation (Figure S2) compared to **1** or **21**. The complete loss of cell potency of all isoxazole substitutions cannot be fully explained by the model. However, this model is consistent with our observation that the aminoisoxazole did not cause perturbation of the maximal UV absorption wavelength when incubated with IDO1 or TDO2 (data not shown), suggesting that it does not bind the heme iron directly. In addition, TDO2 biochemical IC₅₀ values increased when a higher tryptophan concentration was used, suggesting that isoxazoles are competitive with the tryptophan substrate. For example, biochemical IC₅₀ of compound **8** shifted from 0.83 to 4.21 μ M when tryptophan concentration was increased from 0.2 to 1 mM. IC₅₀ of compound **10** shifted from 0.50 to 2.94 μ M when tryptophan concentration was increased from 0.2 to 1 mM.

Selected compounds were also tested in an IDO1 cell-based assay. As shown in Table 4, the compounds showed modest TDO2 selectivity over IDO1, ranging from 6- to 14-fold.

Table 4. TDO2 selectivity over IDO1

Compound	TDO2 selectivity ^a (fold)
1	13×
3	12×
17	14×
21	6×

^aCalculated as IDO1 EC₅₀/TDO2 EC₅₀.

As TDO2 is a heme-containing enzyme, we tested the compounds in cytochrome P450 (CYP) inhibition assays and found that the 5-aminoisoxazole analogs did not inhibit common drug-metabolizing CYP enzymes. For instance, the most potent compounds **1**, **17**, **18**, and **21** all had IC₅₀s greater than 10 μ M for all the CYP isoforms that were tested (CYP3A4, CYP1A2, CYP2D6, CYP2C9, and CYP2C19).

We also investigated the stability of select compounds in whole blood to predict the *in vivo* stability (Table 5). The original HTS hit **1**, the *N*-methylated analog **3**, and thiophene **17** demonstrated poor stability in rat, dog, and human whole blood. The 3-methylisoxazole analog **7** showed improved whole blood stability but with significantly reduced TDO2 potency. However, pyrazole analog **21** demonstrated improved human

Table 5. Whole Blood Stability^a

Compound	% remaining	% remaining	% remaining
	rat	dog	human
1	0	0	0
3	0.1	0.1	0.3
17 ^b	3	3	NT
7	50	65	84
21	NT	NT	91

^aCompounds (2 μ L, 0.5 mM) were incubated in 100 μ L of fresh blood for 2 h unless otherwise stated. Parent remaining is analyzed by LC–MS/MS and reported as a percentage. NT: not tested. ^bIncubated for 30 min.

whole blood stability while maintaining TDO2 potency. The cause of the observed whole blood instability is not well understood at this time.²⁸

In summary, high-throughput screening identified a series of 5-aminoisoxazole compounds as potent TDO2 inhibitors. Medicinal chemistry investigations revealed that both the amino group and the isoxazole moiety were important for TDO2 inhibitory activity, and a hypothetical binding mode was developed through molecular modeling, providing insight into the observed SAR. Optimized compound **21** is a potent TDO2 inhibitor with modest selectivity over IDO1, no observed CYP inhibition, and improved human whole blood stability over the original HTS hit. However, the mechanism of whole blood instability for this series, and relationship with structure, remained unclear. As a result, this series was deprioritized for further optimization in light of alternative, more promising chemical matters.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.7b00427.

Experimental procedures, cell versus biochemical potencies, and quantum mechanical torsional energy analysis (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 1(650)467-3995. Fax: 1(650)467-5155. E-mail: sellers.benjamin@gene.com.

ORCID

Benjamin D. Sellers: 0000-0002-4194-1240

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Genentech analytical chemistry group.

■ ABBREVIATIONS

IDO, indoleamine 2,3-dioxygenase; TDO, tryptophan 2,3-dioxygenase; NFK, *N*-formyl kynurenine; Kyn, kynurenine; AhR, aryl hydrocarbon receptor; Treg, regulatory T cell; Teff, effector T cell; P450, cytochrome P450

■ REFERENCES

- (1) Chen, L.; Flies, D. B. Molecular mechanisms of T cell costimulation and co-inhibition. *Nat. Rev. Immunol.* **2013**, *13*, 227–242.
- (2) van Baren, N.; Van den Eynde, B. J. Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan. *Cancer Immunol. Res.* **2015**, *3*, 978–985.
- (3) Lindstrom, N.; Aittoniemi, J.; Jylhava, J.; Eklund, C.; Hurme, M.; Paavonen, T.; Oja, S. S.; Itala-Remes, M.; Sinisalo, M. Indoleamine 2,3-Dioxygenase Activity and Expression in Patients With Chronic Lymphocytic Leukemia. *Clinical Lymphoma Myeloma & Leukemia* **2012**, *12*, 363–365.
- (4) Jia, Y.; Wang, H.; Wang, Y.; Wang, T.; Wang, M.; Ma, M.; Duan, Y.; Meng, X.; Liu, L. Low expression of Bin1, along with high

expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. *Int. J. Cancer* **2015**, *137*, 1095–1106.

(5) Munn, D. H.; Sharma, M. D.; Baban, B.; Harding, H. P.; Zhang, Y.; Ron, D.; Mellor, A. L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. *Immunity* **2005**, *22*, 633–642.

(6) Opitz, C. A.; Litzenburger, U. M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; Jugold, M.; Guillemin, G. L.; Miller, C. L.; Lutz, C.; Radlwimmer, B.; Lehmann, I.; von Deimling, A.; Wick, W.; Platten, M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature* **2011**, *478*, 197–203.

(7) Koblisch, H. K.; Hansbury, M. J.; Bowman, K. J.; Yang, G.; Neilan, C. L.; Haley, P. J.; Burn, T. C.; Waeltz, P.; Sparks, R. B.; Yue, E. W.; Combs, A. P.; Scherle, P. A.; Vaddi, K.; Fridman, J. S. Hydroxyamidines inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. *Mol. Cancer Ther.* **2010**, *9*, 489–498.

(8) Liu, X.; Shin, N.; Koblisch, H. K.; Yang, G.; Wang, Q.; Wang, K.; Leffert, L.; Hansbury, M. J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K. J.; Polam, P.; Sparks, R. B.; Yue, E. W.; Li, Y.; Wynn, R.; Fridman, J. S.; Burn, T. C.; Combs, A. P.; Newton, R. C.; Scherle, P. A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. *Blood* **2010**, *115*, 3520–3530.

(9) Yan, Y.; Zhang, G.-X.; Gran, B.; Fallarino, F.; Yu, S.; Li, H.; Cullimore, M. L.; Rostami, A.; Xu, H. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. *J. Immunol.* **2010**, *185*, 5953–5961.

(10) Novikov, O.; Wang, Z.; Stanford, E. A.; Parks, A. J.; Ramirez-Cardenas, A.; Landesman, E.; Lakloul, I.; Sarita-Reyes, C.; Gusenleitner, D.; Li, A.; Monti, S.; Manteiga, S.; Lee, K.; Sherr, D. H. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. *Mol. Pharmacol.* **2016**, *90*, 674–688.

(11) Bessedé, A.; Gargaro, M.; Pallotta, M. T.; Martino, D.; Servillo, G.; Brunacci, C.; Biciato, S.; Mazza, E. M.; Macchiarulo, A.; Vacca, C.; Iannitti, R.; Tissi, L.; Volpi, C.; Belladonna, M. L.; Orabona, C.; Bianchi, R.; Lanz, T. V.; Platten, M.; Della Fazio, M. A.; Piobbico, D.; Zelante, T.; Funakoshi, H.; Nakamura, T.; Gilot, D.; Denison, M. S.; Guillemin, G. J.; DuHadaway, J. B.; Prendergast, G. C.; Metz, R.; Geffard, M.; Boon, L.; Pirro, M.; Iorio, A.; Veyret, B.; Romani, L.; Grohmann, U.; Fallarino, F.; Puccetti, P. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. *Nature* **2014**, *511*, 184–190.

(12) Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolusic, E.; Frédérick, R.; De Plaen, E.; Uyttenhove, C.; Wouters, J.; Masereel, B.; Van den Eynde, B. J. *PNAS. Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 2497–502.

(13) Holmgaard, R. B.; Zamarin, D.; Munn, D. H.; Wolchok, J. D.; Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *J. Exp. Med.* **2013**, *210*, 1389–1402.

(14) Spranger, S.; Koblisch, H. K.; Horton, B.; Scherle, P. A.; Newton, R.; Gajewski, T. F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. *J. Immunother. Cancer* **2014**, *2*, 3–16.

(15) Gangadhar, T. C.; Hamid, O.; Smith, D. C.; Bauer, T. M.; Wasser, J. S.; Olszanski, A. J.; Luke, J. J.; Balmanoukian, A. S.; Kaufman, D. R.; Zhao, Y.; Maleski, J.; Jones, M. J.; Leopold, L.; Gajewski, T. F. Epcadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037. *Annals of Oncology* **2016**, *27* (6), 1110PD DOI: 10.1093/annonc/mdw379.06.

(16) For reviews, see: (a) Rohrig, U. F.; Majjigapu, S. R.; Vogel, P.; Zoete, V.; Michielin, O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1). *J. Med. Chem.* **2015**, *58*, 9421–9437.

(b) Qian, S.; Zhang, M.; He, Y.; Wang, W.; Wang, Z. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery. *RSC Adv.* **2016**, *6*, 7575–81.

(17) Yue, E. W.; Douthy, B.; Wayland, B.; Bower, M.; Liu, X.; Leffert, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblisch, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. *J. Med. Chem.* **2009**, *52*, 7364–7367.

(18) Rohrig, U. F.; Majjigapu, S. R.; Grosdidier, A.; Bron, S.; Stroobant, V.; Pilotte, L.; Colau, D.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Michielin, O. Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition. *J. Med. Chem.* **2012**, *55*, 5270–90.

(19) Dolusic, E.; Larrieu, P.; Blanc, S.; Sapunaric, F.; Norberg, B.; Moineaux, L.; Colette, D.; Stroobant, V.; Pilotte, L.; Colau, D.; Ferain, T.; Fraser, G.; Galeni, M.; Frere, J.-M.; Masereel, B.; Van den Eynde, B.; Wouters, J.; Frederick, R. *Bioorg. Med. Chem.* **2011**, *19*, 1550–1561.

(20) Tojo, S.; Kohno, T.; Tanaka, T.; Kamioka, S.; Ota, Y.; Ishii, T.; Kamimoto, K.; Asano, S.; Isobe, Y. Crystal Structures and Structure–Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. *ACS Med. Chem. Lett.* **2014**, *5*, 1119–1123.

(21) Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolusic, E.; Frederick, R.; De Plaen, E.; Uyttenhove, C.; Wouters, J.; Masereel, B.; Van den Eynde, B. J. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 2497.

(22) Structurally similar aminoisoxazoles were disclosed in a patent application: Cowley, P.; Wise, A. Pharmaceutical Compounds. WO 2016026772 A1.

(23) Cowley, P.; Wise, A. Pharmaceutical Compounds. WO 2015082499 A2.

(24) Cowley, P.; Wise, A. Pharmaceutical Compounds. WO 2016071293 A2.

(25) Li, Q.; Gao, D. Fused-ring compounds, pharmaceutical composition and uses thereof. WO 2016131381.

(26) Cowley, P.; Wise, A.; Brown, T. J.; McGowan, M. A.; Zhou, H.; Han, Y. Pharmaceutical Compounds. WO 2017007700 A1.

(27) Lewis-Ballester, A.; Forouhar, F.; Kim, S.-M.; Lew, S.; Wang, Y.; Karkashon, S.; Seetharaman, J.; Batabyal, D.; Chiang, B.-Y.; Hussain, M.; Correia, M. A.; Yeh, S.-R.; Tong, L. Molecular Basis for Catalysis and Substrate-Mediated Cellular Stabilization of Human Tryptophan 2,3-Dioxygenase. *Sci. Rep.* **2016**, *6*, 35169–81.

(28) For an example of isoxazole instability, see: Kalgutkar, A. S.; Nguyen, H. T.; Vaz, A. D. N.; Doan, A.; Dalvie, D. K.; McLeod, D. G.; Murray, J. C. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent leflunomide to its active – cyanoenol metabolite A771726: mechanistic similarities with the cytochrome p450-catalyzed dehydration of aldoximes. *Drug Metab. Dispos.* **2003**, *31*, 1240–50 We could not verify that the mechanism proposed in this paper was operative in our molecules.